Analysts Issue Forecasts for FDMT FY2026 Earnings

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) – Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of 4D Molecular Therapeutics in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer expects that the company will post earnings of ($2.86) per share for the year. The consensus estimate for 4D Molecular Therapeutics’ current full-year earnings is ($2.84) per share.

Several other equities analysts also recently commented on the stock. Bank of America decreased their price objective on shares of 4D Molecular Therapeutics from $42.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, March 10th. The Goldman Sachs Group cut their price objective on shares of 4D Molecular Therapeutics from $51.00 to $44.00 and set a “buy” rating for the company in a research report on Friday, May 9th. Royal Bank of Canada dropped their target price on shares of 4D Molecular Therapeutics from $39.00 to $35.00 and set an “outperform” rating for the company in a report on Monday, March 3rd. HC Wainwright reissued a “buy” rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Monday, March 3rd. Finally, Chardan Capital dropped their price objective on shares of 4D Molecular Therapeutics from $28.00 to $25.00 and set a “buy” rating for the company in a report on Friday, May 9th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $29.56.

4D Molecular Therapeutics Trading Down 2.5%

Shares of FDMT opened at $4.36 on Wednesday. The company has a market cap of $201.98 million, a price-to-earnings ratio of -1.53 and a beta of 2.84. 4D Molecular Therapeutics has a 1-year low of $2.24 and a 1-year high of $28.93. The company’s fifty day simple moving average is $3.37 and its 200 day simple moving average is $4.58.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.02).

Institutional Investors Weigh In On 4D Molecular Therapeutics

Large investors have recently bought and sold shares of the business. BVF Inc. IL boosted its position in 4D Molecular Therapeutics by 70.8% in the first quarter. BVF Inc. IL now owns 4,561,289 shares of the company’s stock worth $14,733,000 after purchasing an additional 1,890,647 shares during the last quarter. Millennium Management LLC boosted its position in 4D Molecular Therapeutics by 1,607.1% in the fourth quarter. Millennium Management LLC now owns 1,420,723 shares of the company’s stock worth $7,913,000 after purchasing an additional 1,337,497 shares during the last quarter. Federated Hermes Inc. boosted its position in 4D Molecular Therapeutics by 33,131.8% in the first quarter. Federated Hermes Inc. now owns 1,250,181 shares of the company’s stock worth $4,038,000 after purchasing an additional 1,246,419 shares during the last quarter. JPMorgan Chase & Co. boosted its position in 4D Molecular Therapeutics by 159.5% in the fourth quarter. JPMorgan Chase & Co. now owns 820,069 shares of the company’s stock worth $4,568,000 after purchasing an additional 504,086 shares during the last quarter. Finally, Norges Bank purchased a new position in 4D Molecular Therapeutics in the fourth quarter worth about $2,790,000. 99.27% of the stock is currently owned by institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.